Home / Transcripts / Tactile Systems Technology, Inc. (TCMD) · November 3, 2025

Tactile Systems Technology, Inc. (TCMD) Earnings Call Transcript

November 3, 2025

NASDAQ US Health Care Health Care Equipment and Supplies earnings 53 min

Earnings Call Speaker Segments

Sam Bentzinger executive
#1

Good afternoon, and thanks for being with us on today's call. Joining me from Tactile's management team are Sheri Dodd, our Chief Executive Officer, and Elaine Birkemeyer, our Chief Financial Officer. Before we get started, please note that what we say and how we answer your questions may include forward-looking statements. Those statements reflect management's current expectations and carry inherent risks and uncertainties. As a result, actual results might differ materially from what those statements indicate, including the risks described in the risk factors section of our annual report on Form 10-K, along with our latest 10-Q filing that will be submitted to the Securities and Exchange Commission. Those factors could be updated periodically in our SEC filings, which you can find on our website. We are not obligated to publicly update or revise any forward-looking statements because of new information, future events, or anything else. Today's call will also mention some financial measures that are not calculated under generally accepted accounting principles, or GAAP; we usually call these non-GAAP financial measures. You can find reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented under GAAP in the earnings press release on the Investor Relations section of our website. With that, I'll hand the call over to Sheri.

Sheri Dodd executive
#2

Thank you, Sam. Hello, everyone, and good afternoon. You're joining us for the earnings call covering our third quarter of 2025. Elaine Birkemeyer, who serves as our Chief Financial Officer, is here alongside me. Today we're eager to walk you through the robust financial and business results we achieved in Q3. These outcomes, as we will explain, show how far we've come on strategy and in running our operations, evidenced by significant strides in transforming the business, innovating on products, and leading the market. During Q3, total revenue came in at $85.8 million, which marks 17% growth compared with the same period last year. Looking at each business line, lymphedema revenue rose 11% versus a year ago, reaching $72.4 million, while airway clearance revenue climbed 71% year-over-year to $13.4 million. We were likewise happy to observe quarter-over-quarter gains across both lines, as lymphedema revenue rose 10% from Q2, and airway clearance revenue — which normally sees a deeper seasonal dip during Q3 — rose 3% from Q2. Gross margins for Q3 were 76%, an 80 basis point improvement year-over-year, and on the bottom line, adjusted EBITDA grew 34% versus last year to $14.4 million. We likewise advanced on our balance sheet through robust cash generation. Thanks to our Q3 results and the momentum we've kept up, we're raising the full-year 2025 revenue outlook to between $317 million and $321 million. That works out to about 8%-10% growth compared with last year. Let me now walk through each business line's performance in more detail and give you updates on where we stand with our main 2025 strategic priorities, which, to recap, focus on the following. One, improving access to care — a core growth pillar for us, since our markets are still deeply underpenetrated. Two, expanding the range of treatment options so patient care improves and our leading market position gets stronger. Additionally, the third priority is increasing patient lifetime value, since the conditions we address are chronic in nature and are supported through our offerings in both products and services. Elaine will next walk through the full results for the third quarter and provide additional details about our updated guidance. A steady recovery continues to be evident in our lymphedema business, and we expect that trend to carry forward. In Q3, lymphedema revenue rose 11% compared with the same period last year and 10% versus the prior quarter, driven by excellent execution of our commercial go-to-market strategy. Having completed two full quarters since rebalancing and optimizing our field sales organization, along with launching a new CRM, we grow more confident that our strategy for field headcount, investments, and embedding Salesforce CRM into day-to-day sales work and productivity visibility is paying off as planned. We finished Q3 with 329 total reps, comfortably above our year-end target of 300 reps, divided about equally between 167 account managers and 162 product specialists; that's a 25% rise in total reps relative to the close of Q1. Thanks to these additions, we now field the largest sales force in Tactile's history, and we've positioned them in the proper roles and geographic areas to satisfy and propel demand. My faith in our field team isn't just about how many people we have, how deep and wide our provider connections run, or the strength of our sales leadership, even though all of those matter greatly. We've achieved strong adoption of our CRM technology and have integrated market data, algorithms, and 3 tech enhancements since July, and all of that enables a data-driven, efficient way of selling. The CRM serves not as a tool for documentation, but as a day-to-day selling guide for spotting opportunities, determining the next best action, catching incomplete order details, and monitoring productivity performance. We've recruited and integrated high-caliber sales representatives, immersing them immediately in training for new hires and giving them early opportunities to gain experience throughout all of our sales channels. The multiplier effect from a strong CRM, support resources within their territories, and targeted channel strategies is now being felt by our veteran account managers. Underpinning our Q4 productivity projections and positioning us favorably for the coming year is our go-to-market approach and staffing ratio of roughly one account manager for every one product specialist across comparable territories. Now turning to examine our Q3 payer mix for lymphedema along with the corresponding year-over-year figures. During this quarter, our Medicare channel experienced a 130% increase compared to the same period last year, whereas our commercial and VA channels declined by 9%. Even though these fluctuations look dramatic, a handful of factors deserve attention. You know that when Medicare administrators changed how they read documentation during the second quarter of 2024, it created a broad obstacle that lasted all year. During that period, we focused on understanding the maximum position and shifted our resources toward call points where VA and commercial patients were more heavily concentrated, since those groups were unaffected by the documentation problems. Because of that, growth in the non-Medicare side of the business was exceptionally robust in the third quarter of last year. After that, we adapted to the updated Medicare documentation rules by rolling out e-prescribing, hiring more back-office staff, executing our go-to-market headcount plan, and redesigning how we handle order management. Although paperwork tied to managing orders isn't going away, we've largely offset the coverage challenge we faced a year ago, and multiple efforts are now in motion to drive scale and operating leverage. Looking at Q3 2025 compared with the same period last year, our payer mix shows what these sweeping policy changes have done. A weaker Medicare comparison is something we're bouncing back from, with help from those freshly launched efforts and a sharper emphasis on vascular practices, even as we contend with tougher results from a year earlier in our commercial and VA channels. The key point is that our Q3 payer mix on its own points to a shift back toward a more typical blended landscape, which we believe will hold, allowing for steadier comparisons against last year going forward. When it comes to our commercial go-to-market strategy, the emphasis is still on putting reps in place across all of our lymphedema call points: VA, oncology, vascular, and lymphatic therapy practices. On top of that, the shift from the LCD to the NCD gives us another tailwind that ought to support further gains in Q4 and afterward. Elaine is going to get into those details soon. Now let's look at how our airway clearance business line did in Q3. This was a terrific quarter following a strong year so far. AffloVest sales rose 71% versus a year ago and 3% from the prior quarter. The primary drivers of Q3's growth are the same ones we've talked about previously. We've established relationships with the 10 largest respiratory DMEs, and among a chosen few of those partners, we've made placement agreements a priority — and our execution across all of them is going well. Demand for AffloVest keeps rising as awareness grows more broadly of bronchiectasis and the treatment choices that exist for it. AffloVest is a terrific product, and we keep capturing additional share of the market. Claims data may be delayed, but we're aware that we're on the verge of becoming the market leader as our commercial momentum picks up speed. Going forward, our attention stays on making each of our top DME relationships stronger and going deeper inside those accounts. Thanks to our field team for airway clearance — highly dedicated and highly capable — we're putting into action a strategy that's been proven: a differentiated product, robust partnerships, and excellent medical education plus training for providers and DME staff. We anticipate that this approach will keep pushing AffloVest penetration toward the 5 million patients in the U.S. who are diagnosed or undiagnosed with bronchiectasis. Now I'd like to offer a few fresh updates on progress across each of our 3 strategic priorities, which are meant to unlock our TAM and make scalable, profitable growth possible. I'll start with an update on our foundational priority, which is improving access to care.

Sheri Dodd executive
#3

During earlier calls, we've noted how generating clinical evidence plays a central part in broadening patient access to care, and being the market leader, it's an honor to be linked with strong evidence generation along with peer-reviewed publications of clinical evidence. Seven days ago, we shared late-breaking data covering six months from our head and neck lymphedema RCT, which had been presented during the American Congress of Rehabilitation Medicine 2025 annual fall conference. That study looked at how effective Flexitouch Plus is relative to usual care among treatment-naive head and neck cancer survivors dealing with lymphedema, and this fresh long-term information comes after an earlier presentation covering two months of data at the ASCO annual meeting in June. The trial was built to back treatment guidelines, patient care pathways, and reimbursement coverage for advanced pump therapy within this population. What we found validates our prior suspicions, and we're delighted to finally possess high-quality data showing Flexitouch Plus delivers sustained long-term effectiveness as an evidence-supported substitute for usual care at six months. Particular ways Flexitouch Plus stands apart from usual care showed diminished internal swelling throughout most anatomical sites, with statistically significant gains reached at two specific sites. Clinician-reported outcome measures covering internal as well as external soft tissue swelling likewise favored Flexitouch Plus relative to usual care. Right now the six-month manuscript sits within the investigator review process and is scheduled for submission in November. Further manuscripts feature a more thorough analysis of usual care, characterizing this trial as therapist-guided lymphedema treatment plus lifelong home-based self-care, slated for submission in early 2026. Meanwhile, we're keeping up active conversations with commercial payers about their existing experimental and investigational policy language concerning head and neck lymphedema, and our goal is to sway those policies and lower obstacles for patients. A second update tied to broadening access to care concerns a recently launched pilot that brings AI-enabled technology into our order operations to boost speed, accuracy, and leverage across the order intake and medical record review processes for traditional non-e-prescribed orders. The pilot's initial phase concentrated specifically on reviewing medical records, which determines whether payer-required medical necessity criteria appear in patient medical records. So far, the pilot's early results have been promising. The tool doesn't just bring efficiency when scanning the records themselves—it also rapidly lets our sales team know what's absent from the medical records. From that point, our team can collaborate more smoothly with provider partners to secure the documentation required. The upcoming phase of the rollout will concentrate on the order intake process, and we're eager to share further details during our next earnings call. Our second strategic priority centers on widening treatment options. Within our lymphedema business line, demand for Nimbl has held steady throughout the third quarter. Nimbl's complete upper and lower extremity offerings debuted merely nine months ago, and feedback from providers and patients alike continues to please us. Nimbl keeps expanding its units faster than the market does, and within a brief stretch we've climbed into a leading spot in the basic pneumatic, non-pneumatic compression pump segment. We're eager to treat additional lymphedema patients using this therapy; when it comes to advanced compression pumps, our product innovation roadmap is advancing nicely, and further specifics will come on the Q4 call. I've got thrilling product innovation updates regarding the airway clearance division. During the start of Q4, we filed a 510(k) with FDA for the next-generation version of AffloVest. That product sits with FDA for review right now, and though we can't yet give additional information about when clearance might arrive, I'm happy to offer a quick peek at the product itself. Reduced weight, added digital connectivity, and better sizing adjustability for a more tailored patient fit rank among the most notable improvements in this new next-generation AffloVest. Patients already prefer the current AffloVest over competing high-velocity chest wall oscillation products, and it works well for managing symptoms tied to bronchiectasis and other airway clearance conditions. We're excited to bring out this next-generation AffloVest, and I think these enhanced features will bolster the patient experience while encouraging adherence. Last, our third strategic priority focuses on boosting lifetime patient value; we see growing chances to strengthen support for lymphedema patients throughout the entire care continuum. That covers more streamlined and personalized engagement prior to, throughout, and following the order and delivery process. Expanding usage and running our patient services organization efficiently is one method we're using here. Patient education consultants, or PECs, who handle most patient product demos and training, plus our back office patient support team, which handles patient advocacy, financial services, clinical and product support, and other patient-related services, make up this organization. Our patients interact directly and most often with these two teams. During the prior quarter, we revealed intentions to start a small care navigation pilot meant to reach out to patients proactively sooner and more reliably across the order process so we can better grasp the moments that matter most for patients to get additional information and strengthen their engagement in the process; this matters since the order progression frequently needs the patient to take action, like following up with their clinician post four weeks of conservative therapy or being available for a product demo and initial treatment; we're proceeding cautiously with care navigation pilots because we want to guarantee efficient scalability, a positive patient experience, and better yield impact. Our initial pilot proved the concept that patients value additional information regarding the order process and expectation setting. A clear need to meet patients where they are by modernizing our communication infrastructure is one outcome we identified. To make this work well, we are putting money into a broad omnichannel system that brings together text, email, chat, self-service, and phone support, so patients get smooth, personalized interaction throughout their journey. Looking ahead, we intend to invest in technology infrastructure here; for now, we will keep using the resources we have to run pilot programs focused on targeted care navigation at important points within the ordering process; through these pilots, we will shape our long-term patient engagement approach and refine communication scripts to improve the patient experience. As our efforts keep widening, we anticipate that care navigation will lessen how much sales reps need to be involved in ordering, assist in reducing patient leakage, and improve overall connectivity and support for patients. As is evident, we are performing strongly across a wide range of strategic priorities, backed by essential investments in our sales organization, order operations, clinical evidence generation, and new product development. As we have said before, these efforts are meant to unlock our TAM and set the business up for lasting profitable growth. We can already observe how these investments are affecting our top line via our commercial go-to-market strategy, and those gains are now starting to reach the bottom line too; during Q3, our profit margin stayed flat compared with a year earlier even with these continuing investments, while adjusted EBITDA increased 34%.

Sheri Dodd executive
#4

Elaine will soon walk through how we're lifting our full-year adjusted EBITDA outlook, which mirrors the growing operating leverage coming out of these investments. Those investments were undertaken for one obvious purpose — fueling profitable growth — and it's encouraging that the payoffs are showing up sooner than we'd anticipated. Ahead of handing things to Elaine, let me give a quick capital allocation update. We've said before that free cash flow generation is treating us better and better, and that should keep going. That gives us room to keep weighing different opportunities for growth and higher shareholder value, and it also lets us kick off a second repurchase program for as much as $25 million of outstanding stock. We see this move and this near-term cash usage as consistent with our confidence in where the business is headed and in our capacity to carry out our financial and operational plans. Make no mistake: a strong balance sheet leaves us many paths for deploying meaningful capital, and we'll keep looking at how to use our market leadership plus our solid commercial and operational footprint to invest and create extra growth. With that, I'll hand it to Elaine for a closer look at our Q3 financial results and an update on what we expect for 2025.

Elaine Birkemeyer executive
#5

Thanks, Sheri. Except where we say otherwise, every figure I mention for the third quarter is GAAP and compared with the same period a year ago. Total revenue for Q3 rose $12.7 million, which is 17%, reaching $85.8 million. Breaking that out by product line: sales and rentals of lymphedema products — that's Flexitouch, Entrée, and Nimbl — were up $7.1 million, or 11%, at $72.4 million. Our airway clearance products, including AffloVest, posted a $5.6 million gain, or 71%, landing at $13.4 million. Moving further down the P&L, gross margin came in at 76% of revenue, versus 75% in the third quarter of 2024. The improvement in gross margin came mainly from reduced manufacturing and warranty costs, which reflect better product design along with stronger collections showing up in our revenue. Operating expenses for the third quarter rose $6 million, or 13%, to $54 million. On a GAAP basis, that operating expense change comprised a $3 million rise in sales and marketing, a $0.2 million rise in research and development, and a $3.3 million rise in reimbursement, general, and administrative, driven largely by strategic investments. Operating income was up $4.2 million, or 62%, to $11 million. Interest income fell $0.3 million, or 31%, to $0.7 million, because our cash position is lower after paying off a term loan. Interest expense dropped $0.3 million, or 63%, to $0.2 million. Income tax expense grew $1.2 million, or 55% year-over-year, to $3.2 million. Net income rose $3.1 million, or 59%, to $8.2 million, which is $0.36 per diluted share, against $5.2 million, or $0.21 per diluted share. Adjusted EBITDA climbed to $14.4 million from $10.7 million; on the balance sheet, we finished the quarter with $66 million of cash and cash equivalents and nothing drawn on our borrowings. Compare that with $94.4 million of cash and $26.3 million drawn as of December 31st, 2024. As we said on the previous call, after Q2 closed we paid off our $24 million term loan and did a refinancing of our revolving credit facility, lifting capacity to $25 million- $40 million from the prior level. If you set aside the debt repayment, our cash balance at the end of the third quarter was $9.2 million higher. Now to walk through our 2025 outlook. For the full year 2025, we're increasing guidance and now anticipate total revenue between $317 million-$321 million, which works out to roughly 8%-10% growth year-over-year. Within our product line, the revised total revenue guidance range assumes lymphedema products grow 3%-4%, while airway clearance products grow 52%-55%. Several key factors drive this updated guidance; beyond the ongoing strength in airway clearance and the lymphedema commercial momentum Sheri described earlier, we're getting a boost from a favorable Medicare policy backdrop, which is a meaningful tailwind for us. As Sheri noted, that comes from the LCD being retired and the shift to the less restrictive NCD, opening up access to advanced pump therapy. We're close to the one-year mark on this transition, and our grasp of the NCD is much sharper now. For patients dealing with complex lymphedema that involves regions like the head, neck, chest, or trunk, advanced pumps such as the Flexitouch are now reachable without having to go through a basic pump trial first; that shift removes a major administrative barrier and speeds up getting people onto the right therapies. Right now we're working hard with providers, educating them about the NCD and stressing the importance of solid documentation. Those with unique clinical conditions now have a straightforward route to coverage for advanced therapy. We think positive effects will start showing up in Q4, with stronger momentum accumulating as we move into next year; when it comes to modeling for the entire 2025 year, our expectation now is GAAP gross margin of roughly 75%. GAAP operating expenses should rise about 11% compared with last year as we put money into our sales organization and push forward on tech-related investments. Interest income comes in at about $1.8 million, the tax rate is 28%, and fully diluted weighted average share count is roughly 23 million shares. Thanks to revenue that beat what we anticipated, our 2025 adjusted EBITDA projection is now about $38 million-$39.5 million. That adjusted EBITDA figure factors in specific non-cash items: stock compensation expense of about $7.8 million, intangible amortization of about $1.3 million, and depreciation expense of about $5.3 million. Last, our expectation for the full-year tariff hit to the business remains about $1 million, following the successful rollout of a variety of tariff mitigation strategies we announced last quarter. Going forward, assuming nothing else shifts, we foresee a continuing yearly impact past 2025 of approximately half that figure. With that, I'll hand the call back to Sheri for some closing remarks. Sheri?

Sheri Dodd executive
#6

Thanks, Elaine. The results we delivered financially and the way we ran the business in Q3 give us growing conviction that we can hit — and beat — what we set out for the whole of 2025. Healthy call points are showing up across both of our business lines. We're building meaningful clinical evidence that backs better access to care for patient groups that are underrepresented right now. The money we've put into our people and into a range of workflow processes is coming through and delivering the returns we anticipated. Our commercial team is strong, well-structured, and positioned to capitalize on the favorable conditions ahead of us in the near term, the medium term, and further out. The path our business is on gives us confidence, and that's what you see in the updated guidance and the new share buyback program. A solid balance sheet gives us many extra avenues for deploying capital in meaningful ways to fuel growth and lift shareholder value. We're eager to finish 2025 strong and to keep delivering in 2026 and afterward. With that, Operator, please open the line for questions.

Kyle Winborne analyst
#7

Hello, Kyle Wynborne here, speaking on behalf of Adam. Nice work on the solid quarter, and we appreciate you fielding our questions. To start, I'd like to dig deeper into how AffloVest did; it was yet another very impressive quarter, and we're eager to learn what keeps fueling that strong showing. You provided useful detail regarding how things are going with the various DMEs. I'm wondering how those individual accounts did during the quarter. Is growth showing up in the majority of them? I'm aware there's also an ongoing push to raise awareness further. Any extra perspective you can offer would help us get a handle on whether this business's growth can be sustained as we head out of 2025 with yet another increase to guidance.

Elaine Birkemeyer executive
#8

Of course. Hello, Kyle. As I mentioned, we're extremely happy with an outstanding quarter for AffloVest. You can see that AffloVest's share of revenue now sits at roughly 16%, compared with 11% a year earlier. I'd love to offer you something with more detail about what's fueling that expansion, but honestly it's precisely what we've described throughout the year. Three strategies are genuinely paying off for us, and we've been developing them for some time, and this year they've truly paid off. First, we hold those strong ties with the 10 biggest DMEs. We don't disclose growth figures or single out any particular one among those where we have relationships — and again, we have them with all 10 — but specific elements are functioning quite well. For one, we hold preferred product placement at a number of those 10 largest DMEs. That means their reps get compensated for this product, so it sits in their respiratory product lineup and they keep selling it and finding suitable placements. Beyond that, we've achieved solid coordination on inventory and on the timing of when they'd like products, in sync with their finance team, so nothing catches them off guard regarding ordering trends. We can maintain our supply chain in a manner that's extremely robust and can meet and sustain demand. On the DME partnership side, everything is proceeding nicely. You're correct that bronchiectasis awareness has grown, and we're contributing to that on two fronts with the medical education we deliver — not only to DMEs throughout their operations staff and their reps, but we also extend that medical education to clinicians directly. That's going quite well, and broader market awareness keeps rising. Finally, and importantly, our product is simply superb. It's differentiated, and we're gaining share and securing this leading market position. Regarding growth, we're also up against what was a fairly weak growth year a year ago. I wouldn't say we're not making projections toward 2026, but nobody should assume we'll see this kind of growth again next year; we're content with our current position. Naturally, AffloVest's expansion has played a part in the overall guidance we're raising for the close of the year, and we'll have more to say about what we believe our 2026 growth ought to be.

Kyle Winborne analyst
#9

That extra detail is really useful. Perhaps, as a follow-up regarding the vest segment, could you offer any insight or jog our memory about where AffloVest stands when it comes to market share? If you cannot really provide specifics on that, maybe you could simply tell us the pace at which this market is expanding, and perhaps some of the wider industry trends, so we understand where it lands within the larger market?

Sheri Dodd executive
#10

Certainly. The main competitors in this area are what I can discuss. For a very long stretch, Baxter has held the top spot. My understanding is they have been selling for more than 30 years. Like we mentioned, we believe we are a very near number one, or possibly already number one, in surpassing them as the leader of this market; regarding how fast the market overall is growing, that is quite difficult to disclose. It is clearly expanding at a double-digit rate. Where that expansion is coming from, I think there are additional therapies now in this area, though what matters more at present, in my view, is simply that awareness of the disease has increased. A pharmaceutical product was introduced, which has contributed to raising awareness broadly. They had a strong presence at certain recent conferences. The positive thing is that whether or not a drug is being used, it truly works alongside vest therapies. As awareness rises, so does our chance to reach the 5 million patients who remain underserved today. We do not expect anything to shift in this market in a negative way, no adverse change.

Kyle Winborne analyst
#11

That's really useful context. Appreciate it, Sheri.

Sheri Dodd executive
#12

All right. Thanks.

Ryan Zimmerman analyst
#13

Hey, Sheri. Hey, Elaine. Congrats on the nice quarter here.

Sheri Dodd executive
#14

Thank you, Ryan.

Elaine Birkemeyer executive
#15

Thank you.

Ryan Zimmerman analyst
#16

I'd like to touch on the guidance for a moment. Elaine, I appreciate the detail you provided on the segments. Let me just confirm what I'm hearing: AffloVest is clearly trending up as we head into the fourth quarter, while lymphedema appears to be declining, perhaps to the low single digits. First, I want to verify that I have that right. When I look at how the business has historically performed moving from 3Q to 4Q, especially in lymphedema, the usual pattern is a bigger step-up than what you seem to be modeling. That's true for the 3Q to 4Q comparison, at least in this year. So I'm just trying to get a handle on it. Was there something in the third quarter that might have been pulled forward or that was one-time in nature, specifically within the lymphedema business? I have a follow-up question as well.

Sheri Dodd executive
#17

Yeah. I'd say nothing got pulled forward. To put things in context versus a year ago — and I bring this up since it's now been 12 months, basically, since I came on board around what was my first quarter — back then, if you recall, the NCD interpretation changed. I know we've discussed LCD — sorry, we've covered that subject plenty. That headwind sent our whole lymphedema business into a significant downturn. Additional documentation became necessary. Considering how many reps we had at that point, the count was far lower than what we have now. Last year the business was simply extremely sluggish, and it dragged on through the rest of the year. Nothing like that is occurring this year. Actually, it's the reverse: we now have a tailwind, beginning with the NCD. We haven't yet seen it fully play out — much of it will come somewhat in Q4, sorry, in Q4 and also into next year — and that's more of a tailwind, whereas previously it was very much a headwind. We did increase our overall guidance for lymphedema. We had it at 1%-2%, and we've lifted that to 3%-4% for the end of this year.

Elaine Birkemeyer executive
#18

Yeah. I think specifically on — go ahead.

Ryan Zimmerman analyst
#19

My apologies, Elaine.

Elaine Birkemeyer executive
#20

What's behind the apparent deceleration in your growth as we head into Q4? I believe this ties into part of what Sheri mentioned. Does that match up with what we saw a year ago? Sadly, Q3 was severely weakened, since we were sitting right at the lowest point of the impact. Recovery began to show in Q4, and then even more going into 2026. That plays a role, I'd say. You brought up the sequential point. True, sequentials came in somewhat differently during this year. We did hint at that. Given the recruiting we're doing, we anticipated it; roughly 30 more reps were brought on board back in Q2. Our headcount was simply far larger by the time Q3 arrived. That naturally produced stronger growth from Q2 into Q3 than what we typically experience. It's likewise softening the Q3-to-Q4 growth somewhat. Sequentials look somewhat different, yet considering the second half as a whole, I'd argue it's actually at the upper end if you consider our sequential year-over-year growth. The Q3, Q4 pattern differs somewhat this year, purely because of the sales rep hiring.

Ryan Zimmerman analyst
#21

Alright, that's quite useful — appreciate the added detail. Turning to roughly question 26. I'm not sure whether you'll want to weigh in on this, but how would you characterize the rate at which the lymphedema market is expanding? The reason I ask is that, as things stand, I believe the street is working on the assumption that you folks can return to that kind of growth in the high single digits for lymphedema come next year. I just want reassurance that, in your view, that isn't an unreasonable expectation. Sheri, I know I definitely put this question to you back when you came on board — namely, do you have anything to say about those longer-term targets that had more or less been laid out prior to your arrival, and do you consider them to be fitting, I suppose? Thanks.

Sheri Dodd executive
#22

Alright, thank you, Ryan. Within lymphedema, the market is expanding by 10%. At this stage, nothing suggests to us that we ought to lag behind that market. I won't say anything about next year, though we definitely hold the view that growth here sits at 10%. Given our products, our sales team, our productivity, plus backing for our back office and all the investments we've made, we think we can land in that same range too. Under our fresh guidance for the close of this year, we move up to somewhere between 8% and 10%. Compared with where we stood at the start of this year, that's a solid recovery. Once again, this rebound comes from growing our sales headcount, from our CRM, from our channel strategies, and from our back office support. Every one of those elements belonged to our plan. They're all gaining traction. We're carrying it out. The momentum is with us. Once more, no guidance is being given for 2026, yet I see no basis for thinking we would perform below the market. That's quite useful. Thank you. Thank you, Ryan.

Brandon Vazquez analyst
#23

Perhaps to start at a broad level, there are numerous favorable dynamics working in your favor right now. That's genuinely heartening. Are there any — perhaps one or two leading programs or reimbursement enhancements — that you'd highlight as fueling the expansion? Honestly, it seems as though this quarter represented something of a turning point for both segments of the business. I'm wondering whether there's something specific you'd point to, or whether it's simply widespread across every initiative?

Sheri Dodd executive
#24

What I'd mention is what appeared in Afshin's remarks, which I already addressed responding to Kyle's earlier question. That one, I believe, simply demonstrates, once more, how our approach is playing out through our DME partnerships, plus expansion of the market as bronchiectasis awareness grows, plus simply excellent products. Regarding the lymphedema area, several developments we're observing are, once again, closely tied to our approach. Our commercial strategy — during Q1, we carried out a rebalancing; we performed an optimization. We explained that we reassessed how many account managers were required relative to how many product specialists were needed. That's what we did. We followed through. You witnessed part of that improvement occurring in Q2. You're witnessing it during Q3, and we will keep witnessing it throughout Q4. Ultimately, this comes down to productivity. Our productivity metric is revenue generated per territory. At this point we have the correct staffing levels in the correct regions with the correct scopes. We will keep watching that take shape and become refined as a multiplier heading into Q4 and heading into 2026. That represents a significant portion of lymphedema expansion from that productivity angle. We're also going to observe, and we'll observe it more during Q4, truly the effect of the NCD. That NCD was made public in November of last year. As a reminder, we weren't trained until February. From February through early summer, there were certain shifts in how they interpreted it. The NCD itself, regarding what the interpretation is, has only truly stood on firm footing for roughly four months now; at present we're making our proper transition and ensuring we're positioned well so that patients meeting the criteria for advanced pump therapy, such as Flexitouch, can reach that immediately rather than having to complete the four-week basic pump trial; that too is working in our favor. We're beginning to observe part of the effect from our initiative. Salesforce, definitely, once again, isn't merely a documentation instrument, but genuinely functions as a job aid. It's what every one of our sales reps turns to for planning their work; we're beginning to notice back-office efficiencies. All of this is likewise being realized not solely on the top line, but we're seeing part of it flow through to the bottom line; we feel extremely well-positioned for ongoing financial results on both the top and bottom line as we head into Q4 and beyond.

Brandon Vazquez analyst
#25

Alright, that's excellent. I've got a couple of quick follow-ups tied to the things you just mentioned. Number one, regarding sales or the rep organization, I believe you mentioned there are 329 reps at present. That puts you past the target of 300. Give us some perspective on what happens next. Do you require additional reps? Are you satisfied with the current Salesforce count? How will that carry into the coming year? The second follow-up concerns the NCD side — if you could take a moment to discuss it. I think you noted that patients now have an easier route onto Flexitouch. Does that mean a shorter cycle? Any information you can share regarding how that route now appears for those patients under the updated NCD would be useful. Many thanks for the questions.

Sheri Dodd executive
#26

Certainly. Regarding the rep angle, we believe our headcount strategy and execution leave us in a strong position. We will add new headcount while maintaining this one-to-one balance. To repeat, a single account manager paired with a single product specialist. Staffing decisions will follow how these territories expand; we're in good shape; we will keep filling that out. We'll reach the appropriate headcount in line with the strategy we established in Q1. When it comes to the NCD, that NCD does provide a route for patients with unique characteristics to move straight to an advanced pump. Those unique characteristics relate to the location of the edema and to various skin conditions. We have better understanding and clearer guidance from the MACs about what they seek on the documentation front. Documentation requirements remain in place; the difference is that a path now exists for such a patient to go straight to that therapy rather than first trying a basic pump therapy. We won't be reporting yet, and we don't report specifically, on the breakdown of what will have shifted. We expect the NCD to act as a tailwind, enabling more patients to go directly to the correct pump for their needs given their conditions. Once more, this is only beginning, yet absent a policy change, we expect the NCD to remain in effect. This is the policy our Medicare patients can advance to while they collaborate with their provider to figure out the appropriate therapy for them. I hope that addresses your question.

Anderson Schock analyst
#27

Hi there. Thanks for letting me ask a few things, and congratulations on such an impressive quarter. To begin, regarding the growth in lymphedema revenue, could you break down what's mainly driving that? Of the lymphedema revenue right now, how much comes from Nimbl as opposed to Flexitouch? Has that proportion settled between the second quarter and the third quarter? And when do you think you'll hit a target mix?

Sheri Dodd executive
#28

Hi, Anderson. Let me take the mix question first. We don't disclose Nimbl versus Flexitouch figures. What we've stated previously, and what I'll say is happening at present, is that Nimbl's growth is outpacing the market. Keep in mind, it's been just under nine months since we fully launched Nimbl as a product. Providers keep adopting it enthusiastically, and so do patients. It's performing remarkably well. It was a wonderful addition. Since launching it, we've secured a market leadership position in the basic pump category. We feel very good about that situation. Thanks to the NCD, there's a path for us to see even more unit growth from Flexitouch. As I said, we won't break those numbers out. We're quite happy with the policy environment as it stands, and with how well Nimbl has done. Flexitouch is an excellent product. We're pleased that patients who need it can obtain direct access, particularly those with head and neck lymphedema, chest lymphedema, trunk lymphedema; a basic pump definitely did not serve these patients before.

Elaine Birkemeyer executive
#29

At this point, I've lost track of your second question. My apologies. I believe it had to do with what's driving lymphedema. Once more, to touch on what I think Sheri mentioned earlier, it was really about adding to our headcount. When you examine it, we've brought on a considerable number of reps — 66 reps, which is 25% above where we stood at the close of Q1. That's substantial growth. As each quarter passes, their tenure grows longer and longer, which translates into better productivity. We have sales reps who are still ramping up, and now there's also the CRM tool, something we never had previously, which doesn't just help them arrange their work but truly pinpoints where their time is best spent and which clinicians are treating a large volume of these lymphedema patients. And finally, that robust airway clearance performance Sheri also brought up.

Anderson Schock analyst
#30

All right, understood. I appreciate that; it's useful. Regarding the rise in recognition and identification of bronchiectasis during Q3 and Q4 after the first drug for that condition won approval in August, what trends are you observing?

Sheri Dodd executive
#31

Did you ask where we're noticing it?

Anderson Schock analyst
#32

So, in terms of diagnosis and growth, what kind of effect are you observing on the bronchiectasis market overall?

Sheri Dodd executive
#33

I definitely think an uplift is happening. When it comes to tackling the total addressable market, one of the larger obstacles has been awareness in the market, for both lymphedema and bronchiectasis — put simply, these patients aren't diagnosed and aren't treated. As a pharmaceutical product launches and money is spent on awareness, my view is that this provides a lift. On top of that, I think there's a gain in market share. I won't credit increased awareness for all of it. Through our DMEs, we know and can observe that growth is occurring in those areas. My belief is that share growth is directly responsible for that as well.

Anderson Schock analyst
#34

All right, understood. Thanks for letting us ask.

Sheri Dodd executive
#35

Of course.

Ben Haynor analyst
#36

Good afternoon. I appreciate you taking my questions. Congratulations on the quarter as well as on the Flexitouch study.

Sheri Dodd executive
#37

Thanks.

Ben Haynor analyst
#38

So about that trial in head and neck cancer — really the lymphedema piece. You said, I believe, that you'd already been talking with some payers, or that conversations with payers are on the horizon. What's a reasonable expectation for how fast those policies might get looked at? Is it necessary for the manuscripts to be published? Is it necessary to wait for the scheduled review cycle to arrive? Or might a few of these groups, a few of these organizations, be able to move somewhat more quickly?

Sheri Dodd executive
#39

Yes, thank you, Ben. When it comes to coverage, we are working with commercial payers and raising their awareness about the policies they currently have in place for lymphedema affecting the head and neck. A lot of these payers have put it in the experimental and investigational category. We recognize this creates an obstacle to market access for patients who might otherwise see benefits from the therapy. These discussions have been happening for a while; we have a dossier ready. We have been reaching out to payers. A large number of them have shown willingness to learn more about what data exists right now, and also to better understand and look further into the policy they currently follow. Overall, they have been quite receptive to our efforts, and we anticipate they will revisit their existing coverage policies. Having said that, the schedule for making policy changes most likely falls more around 2026. This aligns closely with our prior experience and with what we have communicated before. I wish it could move more quickly; they operate on a policy review calendar, and a few of them will conduct reviews outside the usual cycle. I'm confident that with the six-month data available, and especially given that this is such a landmark study demonstrating the benefit of Flexitouch, particularly among treatment-naive patients — these being patients who never got a basic pump, and who have also never undergone therapist-guided lymphatic therapy — we will be in a position to hold a truly robust conversation. My expectation is that the more significant policy shifts will occur more toward 2026. Sadly, likely spread across that entire year, not necessarily right at the start.

Ben Haynor analyst
#40

Understood. I appreciate that extra detail. One final item from my side: you've already carried out strategic improvements, portfolio adjustments, and certain internal technology enhancements. As those moves continue to unfold, how would you describe which stage we're in for the eventual effect on revenue growth and expense leverage?

Sheri Dodd executive
#41

Absolutely. I'm glad we're beginning to witness those results show up. In my view, that's surpassing what we'd anticipated. Let me unpack each of these separately. Regarding the CRM platform on its own — okay, so it was implemented. We understood it would boost efficiency, yet we additionally brought on more than 50 sales personnel from Q2 through Q3. That's a 25% rise, in fact, since the year started we've grown our sales team. These newer reps are beginning to utilize the system, the Salesforce system, whereas our longer-tenured reps needed to transition away from their prior manual methods over to the CRM; we'll keep realizing the advantages from that, and we aren't halting our spending. We'll keep polishing that system, enhancing it for the reps, assisting them in truly grasping which prospect is strongest, where they ought to focus. We'll be examining how to fold more of our back-office or order-processing components into Salesforce too; it essentially becomes the definitive system, not merely for CRM tasks that sales reps perform, but for the order itself. This represents a major portion of the funding we're directing toward the coming year. We've already allocated money this year; it will keep developing next year. When you discuss innings, not exactly resembling the World Series in which you finish in seven games and your club either triumphed or fell short, this will be a continuous contest. Our pledge has consistently been that we required certain of those funds during 2025 to propel us forward. We promised to keep demonstrating a return on that spending. I brought up our care navigation; we're going to launch additional parts of that omnichannel platform starting next year; that will generate returns, though those returns will arrive in late 2026 and stretch into 2027. Our spending on Salesforce, a major buildup in investment funds right now, that will pay off through order operations efficiency and yield. Leverage, every one of those outcomes will materialize; we are overhauling our business, both regarding how that go-to-market approach is structured, and also that order process simplification and making it simpler. We recognize that will deliver a return. It'll be a game with multiple endings, yet we keep our pledge to be capable of demonstrating a return on that spending; we'll be preparing much of that when we discuss our 2026 plan once we're all reunited at the start of next year.

Ben Haynor analyst
#42

Got it. Thanks for the commentary there. Congrats again.

Sheri Dodd executive
#43

Thank you

Elaine Birkemeyer executive
#44

Thank you.

Operator operator
#45

Everyone, we appreciate you joining; that wraps up today’s teleconference. You’re welcome to hang up now, and we hope the rest of your day is great.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Tactile Systems Technology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Tactile Systems Technology, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.